Please ensure Javascript is enabled for purposes of website accessibility

Tilray to Ship First-Ever Commercial Medical Pot Delivery to Israel

By Eric Volkman - Jan 3, 2020 at 9:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The internationally focused company says the Middle Eastern nation will be its 15th export market.

Ever eager to enlarge its footprint around the world, Tilray (TLRY) will make history by being what it claims is the first cannabis company to import medical marijuana into Israel for commercial use.

The Canada-based company said Monday it signed an import-export agreement with an Israeli company, Canndoc, for medical cannabis. Under the terms of the deal, Tilray is to ship up to 2.5 metric tons of product to the Middle Eastern country. Tilray said the delivery, which will originate from company facilities in Portugal, should arrive early this month. It will be sold in Israeli pharmacies.

Although the temperate Israeli climate is suitable for growing cannabis, the country is currently experiencing a shortage of product. Some claim that this arises from reforms enacted last May, which aim to shift the point of sale to licensed pharmacies rather than directly from growers. These reforms also mandate that growers conform to Good Manufacturing Practices (GMP) standards.

An Israeli flag design superimposed over marijuana flowers.

Image source: Getty Images.

The other part of the agreement obliges Tilray to buy up to five metric tons of cannabis flower from Canndoc starting in the middle of this year. This product is to be shipped to that Tilray outpost in Portugal and is contingent upon Canndoc receiving an export license. If it does not do so, the flower will be developed into medical cannabis and sold within Israel either under the Tilray name or co-branded by the two companies.

Canndoc is a subsidiary of Israeli medical-sector holding company InterCure and holds a license to grow and sell medical cannabis. According to Tilray, Canndoc -- founded in 2008 -- was the first publicly traded Israeli company active in that segment of the marijuana market.

Like many countries outside of North America, Israel permits the use of medical marijuana, albeit with a set of restrictions. Recreational use, although still technically illegal, has been decriminalized.

In the press release trumpeting the deal, Tilray said that Israel will become the 15th country targeted by its exports. One pillar of the company's strategy is to become a supplier to markets around the world. Last month, Tilray announced it had made its inaugural shipment of medical cannabis extracts to Switzerland. That country, like Israel, permits the sale and consumption of medical cannabis only.

Tilray was not shy about pointing out that it was the first licensed company to export medical cannabis product from North America.

Despite this news of Tilray's continued international expansion, investors traded the marijuana stock down on the day. It closed just over 4% lower Monday.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.